Impact of Rapid Susceptibility Testing and Antibiotic Selection Strategy on the Emergence and Spread of Antibiotic Resistance in Gonorrhea

J Infect Dis. 2017 Nov 27;216(9):1141-1149. doi: 10.1093/infdis/jix450.

Abstract

Background: Increasing antibiotic resistance limits treatment options for gonorrhea. We examined the impact of a hypothetical point-of-care (POC) test reporting antibiotic susceptibility profiles on slowing resistance spread.

Methods: A mathematical model describing gonorrhea transmission incorporated resistance emergence probabilities and fitness costs associated with resistance based on characteristics of ciprofloxacin (A), azithromycin (B), and ceftriaxone (C). We evaluated time to 1% and 5% prevalence of resistant strains among all isolates with the following: (1) empiric treatment (B and C), and treatment guided by POC tests determining susceptibility to (2) A only and (3) all 3 antibiotics.

Results: Continued empiric treatment without POC testing was projected to result in >5% of isolates being resistant to both B and C within 15 years. Use of either POC test in 10% of identified cases delayed this by 5 years. The 3 antibiotic POC test delayed the time to reach 1% prevalence of triply-resistant strains by 6 years, whereas the A-only test resulted in no delay. Results were less sensitive to assumptions about fitness costs and test characteristics with increasing test uptake.

Conclusions: Rapid diagnostics reporting antibiotic susceptibility may extend the usefulness of existing antibiotics for gonorrhea treatment, but ongoing monitoring of resistance patterns will be critical.

Keywords: antibiotic resistance; gonorrhea; mathematical model; point-of-care test.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / therapeutic use
  • Ceftriaxone / therapeutic use
  • Ciprofloxacin / therapeutic use
  • Disease Transmission, Infectious / statistics & numerical data*
  • Drug Resistance, Microbial / drug effects*
  • Gonorrhea / drug therapy*
  • Gonorrhea / transmission*
  • Humans
  • Microbial Sensitivity Tests / methods
  • Models, Theoretical
  • Neisseria gonorrhoeae / drug effects*
  • Point-of-Care Systems / statistics & numerical data*

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Ceftriaxone
  • Azithromycin